Last reviewed · How we verify
NOE-105
At a glance
| Generic name | NOE-105 |
|---|---|
| Also known as | Escalating dose levels of NOE-105 |
| Sponsor | Noema Pharma AG |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette Syndrome (PHASE2)
- A 10-week Efficacy Study of NOE-105 in Childhood Onset Fluency Disorder (Orpheus) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NOE-105 CI brief — competitive landscape report
- NOE-105 updates RSS · CI watch RSS
- Noema Pharma AG portfolio CI